Breakthrough vaccine could help cure pancreatic cancer

Early trial results suggest personalised vaccines could stop deadly disease returning

<p>A new vaccine developed using the same technology as the BioNTech-Pfizer Covid jab could be key to curing pancreatic cancer</p>

A new vaccine developed using the same technology as the BioNTech-Pfizer Covid jab could be key to curing pancreatic cancer

A new vaccine developed using the same technology as the BioNTech-Pfizer Covid jab has raised hopes of a cure for pancreatic cancer.

In early trial results of the jab - which uses mRNA theory and is designed to prevent tumours from returning after surgery - half of the patients given a vaccine remained cancer free 18 months later.

The inoculation, developed by scientists working with pharmaceutical firm BioNTech and US company Genentech, has raised hopes of finally finding a cure for the deadliest common cancer which claims the lives of 90 per cent of patients within two years of diagnosis.

The results of the groundbreaking trial, led by Dr Vinod Balachandran at the Memorial Sloan Kettering Cancer Centre in New York, were presented at the American Society of Clinical Oncology conference in Chicago.

They showed personalised vaccines could train the immune system to kill cells associated with pancreatic cancer.

A similar trial is also currently underway for bowel cancer – and Moderna, another Covid vaccine manufacturer, is also developing mNRA treatments for cancer and autoimmune conditions.

The early-stage pancreatic cancer trial involved 16 patients, who were given eight doses of a vaccine intravenously after surgery to remove a tumour.

The jabs were custom-made for each person using mRNA genetic code found in their tumours to teach cells to make a protein that will trigger an immune response.

This enables the body to detect any cancer cells as a threat and T cells, a type of white blood cell, then destroy them.

The vaccine triggered a T-Cell response in half the patients, who all remained cancer-free throughout the study.

Of the remaining eight patients who did not respond to the vaccine, six died or saw their cancer return.

BioNTech said the preliminary results showed “a favourable safety profile as well as encouraging signs of clinical activity”.

Prof Özlem Türeci, co-founder and chief medical officer at BioNTech, said: “With only under 5 per cent of patients responding to current treatment options, PDAC is one of the highest unmet medical need cancers.

“We are committed to take up this challenge by leveraging our long-standing research in cancer vaccinology and are trying to break new ground in the treatment of such hard-to-treat tumours.

“The results of this Phase 1 study are encouraging. We look forward to further evaluating these early results in a larger randomized study.”

Dr Balachandran added: “Unlike some of the other immunotherapies, these mRNA vaccines do appear to have the ability to stimulate immune responses in pancreatic cancer patients.

“So we’re very excited about that, and the early results that suggest that if you have an immune response you may have a better outcome.”

Register for free to continue reading

Registration is a free and easy way to support our truly independent journalism

By registering, you will also enjoy limited access to Premium articles, exclusive newsletters, commenting, and virtual events with our leading journalists

Please enter a valid email
Please enter a valid email
Must be at least 6 characters, include an upper and lower case character and a number
Must be at least 6 characters, include an upper and lower case character and a number
Must be at least 6 characters, include an upper and lower case character and a number
Please enter your first name
Special characters aren’t allowed
Please enter a name between 1 and 40 characters
Please enter your last name
Special characters aren’t allowed
Please enter a name between 1 and 40 characters
You must be over 18 years old to register
You must be over 18 years old to register
Opt-out-policy
You can opt-out at any time by signing in to your account to manage your preferences. Each email has a link to unsubscribe.

By clicking ‘Create my account’ you confirm that your data has been entered correctly and you have read and agree to our Terms of use, Cookie policy and Privacy notice.

This site is protected by reCAPTCHA and the Google Privacy policy and Terms of service apply.

Already have an account? sign in

By clicking ‘Register’ you confirm that your data has been entered correctly and you have read and agree to our Terms of use, Cookie policy and Privacy notice.

This site is protected by reCAPTCHA and the Google Privacy policy and Terms of service apply.

Register for free to continue reading

Registration is a free and easy way to support our truly independent journalism

By registering, you will also enjoy limited access to Premium articles, exclusive newsletters, commenting, and virtual events with our leading journalists

Already have an account? sign in

By clicking ‘Register’ you confirm that your data has been entered correctly and you have read and agree to our Terms of use, Cookie policy and Privacy notice.

This site is protected by reCAPTCHA and the Google Privacy policy and Terms of service apply.

Join our new commenting forum

Join thought-provoking conversations, follow other Independent readers and see their replies

Comments

Thank you for registering

Please refresh the page or navigate to another page on the site to be automatically logged inPlease refresh your browser to be logged in